Bordetella pertussis infections continue to rise!
In contrast to the time before and during the Covid pandemic, we are currently seeing alarmingly high numbers of respiratory infections caused by bacteria. Especially the high number of Bordetella pertussis detections are being discussed in the press across Europe.
B. pertussis is the main pathogen that causes whooping cough and humans are the only reservoir. Despite the availability of vaccines, major outbreaks continue to occur worldwide. B. pertussis is highly contagious and there is an increased need for action, especially for infants and small children, as well as older people or people with respiratory diseases, in the event of infection, as the course can be extremely critical.
The latest figures from Europe show an extreme increase in diagnostic analyses and confirmed case numbers. In proportion, more cases were registered in the first quarter of 2024 than in the whole of 2023. The ECDC has already released an acute risk report on this.
With the RIDA®family product line, R-Biopharm offers safe and simple molecular diagnostics for the direct detection and differentiation of Bordetella pertussis in your laboratory routine. Our RIDA®GENE Bordetella, RIDA®CARE (Vivalytic Bordetella) and our Tandem®Plex solutions reliably detect Bordetella and also cover relevant co-infections.
